Stephens raised the firm’s price target on BrightSpring Health (BTSG) to $64 from $53 and keeps an Overweight rating on the shares. BrightSpring’s 7% revenue and 12% EBITDA beat was “among the cleanest 1Q26 prints of our coverage,” the analyst tells investors in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $61 from $50 at Wells Fargo
- BrightSpring Health price target raised to $60 from $55 at KeyBanc
- BrightSpring Earnings Call Highlights Strong Growth Momentum
- BrightSpring Health price target raised to $60 from $52 at BMO Capital
- BrightSpring Health reports Q1 adjusted EPS 39c, consensus 31c